Seattle Genetics (SGEN) Given Media Impact Rating of 0.21

News stories about Seattle Genetics (NASDAQ:SGEN) have been trending somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Seattle Genetics earned a news impact score of 0.21 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.4077729872478 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:

Seattle Genetics (SGEN) opened at $50.54 on Friday. Seattle Genetics has a 1-year low of $45.31 and a 1-year high of $71.32. The stock has a market cap of $7,270.00, a price-to-earnings ratio of -56.79 and a beta of 2.08.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.02. Seattle Genetics had a negative net margin of 26.03% and a negative return on equity of 33.36%. The business had revenue of $129.61 million for the quarter, compared to analyst estimates of $123.99 million. During the same period in the previous year, the company earned ($0.39) earnings per share. The business’s revenue for the quarter was up 23.1% on a year-over-year basis. analysts predict that Seattle Genetics will post -1.25 EPS for the current fiscal year.

SGEN has been the topic of several research reports. Jefferies Group reissued a “buy” rating and set a $53.00 price objective on shares of Seattle Genetics in a report on Thursday, October 26th. Cantor Fitzgerald set a $50.00 price objective on shares of Seattle Genetics and gave the company a “hold” rating in a report on Monday, January 8th. Morgan Stanley lifted their price objective on shares of Seattle Genetics from $64.00 to $69.00 and gave the company an “overweight” rating in a report on Tuesday, October 31st. Royal Bank of Canada lifted their price objective on shares of Seattle Genetics from $68.00 to $69.00 and gave the company an “outperform” rating in a report on Monday, November 13th. Finally, HC Wainwright reissued a “buy” rating on shares of Seattle Genetics in a report on Wednesday. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $64.56.

In other news, Director Marc E. Lippman sold 3,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $58.07, for a total transaction of $174,210.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bros. Advisors Lp Baker acquired 3,846,153 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were bought at an average cost of $52.00 per share, for a total transaction of $199,999,956.00. The disclosure for this purchase can be found here. Insiders sold 98,993 shares of company stock worth $5,603,714 over the last ninety days. Corporate insiders own 34.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Seattle Genetics (SGEN) Given Media Impact Rating of 0.21” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply